Migdal Insurance & Financial Holdings’s Neurocrine Biosciences NBIX Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30K	Buy	+178	New	+$26.4K	﹤0.01%	296

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Migdal Insurance & Financial Holdings's NBIX Position: Q2 2026 in Review

Migdal Insurance & Financial Holdings opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 178 shares worth $30K. The stake represents ﹤0.01% of the portfolio and ranks #296 among its holdings.

771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Migdal Insurance & Financial Holdings held 178 shares of Neurocrine Biosciences worth $30K as of Q2 2026.
Neurocrine Biosciences was a new Migdal Insurance & Financial Holdings position in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of Migdal Insurance & Financial Holdings's portfolio in Q2 2026, its #296 holding.
771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q2 2026, filed 10 Aug 2026.